Abstract
Aim. An evidence review on use of bismuth in irritable bowel syndrome.Key points. Irritable bowel syndrome (IBS) is a common functional disorder significantly impacting the quality of life and social status, i.a., through frequent manifestations of diarrhea. Postinfectious IBS emerges after a bacterial, pro-tozoan or viral intestinal disease. The new coronavirus pandemic supposedly affects most factors involved in functional disorder developments and may serve a fuelling cause of postinfectious IBS. Bismuth salts accumulate cytoprotective, anti-inflammatory and antibacterial properties. Therapeutic efficacy of bismuth compounds has been demonstrated in treatment of diarrhea-accompanied diseases of various etiology, including postinfectious IBS. The use of therapeutic-dosed bismuth preparations is safe and well tolerated by patients.Conclusion. Use of bismuth may be considered a treatment and prevention approach in diarrhea-predominant IBS, both in monotherapy and combined regimens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Russian Journal of Gastroenterology, Hepatology, Coloproctology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
